An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
18 10 2023
Historique:
medline: 23 10 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: ppublish

Résumé

In contrast to the checkerboard method, bactericidal experiments [time-kill curves (TKCs)] allow an assessment of pharmacodynamic (PD) interactions over time. However, TKCs in combination pose interpretation problems. The objective of this study was to characterize the PD interaction over time between ceftazidime/avibactam (CZA) and colistin (CST) using TKC against four multidrug-resistant

Identifiants

pubmed: 37681977
doi: 10.1128/aac.00301-23
pmc: PMC10583682
doi:

Substances chimiques

Ceftazidime 9M416Z9QNR
Colistin Z67X93HJG1
avibactam 7352665165
Anti-Bacterial Agents 0
Azabicyclo Compounds 0
Drug Combinations 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0030123

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Pharmacokinet Pharmacodyn. 2014 Feb;41(1):15-33
pubmed: 24317870
J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):509-520
pubmed: 28887735
Clin Infect Dis. 2016 Jul 15;63(2):234-41
pubmed: 27098166
Antimicrob Agents Chemother. 2015 Sep;59(9):5602-10
pubmed: 26124169
Int J Antimicrob Agents. 2016 Dec;48(6):607-613
pubmed: 27865626
CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):525-537
pubmed: 31056834
Clin Microbiol Infect. 2018 Jul;24(7):697-706
pubmed: 29229429
J Insect Sci. 2003;3:34
pubmed: 15841249
Front Pharmacol. 2021 Oct 29;12:770518
pubmed: 34776982
J Antimicrob Chemother. 2019 Jun 1;74(6):1521-1530
pubmed: 30863849
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031201
J Antimicrob Chemother. 2020 Feb 1;75(2):400-408
pubmed: 31670804
MethodsX. 2021 Oct 11;8:101543
pubmed: 34754811
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0089021
pubmed: 34228551
J Clin Pharmacol. 2023 Feb;63(2):151-165
pubmed: 36088583
J Glob Antimicrob Resist. 2020 Sep;22:18-27
pubmed: 31863899
Clin Microbiol Infect. 2018 Jul;24(7):687-688
pubmed: 29649606
J Antimicrob Chemother. 2016 May;71(5):1279-90
pubmed: 26850719
Nat Commun. 2021 Jul 7;12(1):4188
pubmed: 34234121
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528
pubmed: 31724045
Nat Rev Microbiol. 2019 Mar;17(3):141-155
pubmed: 30683887
Clin Microbiol Infect. 2020 Dec;26(12):1644-1650
pubmed: 32213316
Clin Microbiol Infect. 2020 Sep;26(9):1254.e9-1254.e15
pubmed: 32006693
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
J Antimicrob Chemother. 2015 May;70(5):1434-42
pubmed: 25712313
Int J Antimicrob Agents. 2022 Sep;60(3):106616
pubmed: 35691605
Antimicrob Agents Chemother. 1997 Jan;41(1):95-100
pubmed: 8980762
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29891598
Clin Microbiol Infect. 2018 Jul;24(7):689-696
pubmed: 29269090
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596
pubmed: 27730482
Pharmacol Rev. 2013 Jun 26;65(3):1053-90
pubmed: 23803529
Int J Antimicrob Agents. 2020 Jun;55(6):105941
pubmed: 32171741
Int J Antimicrob Agents. 2021 May;57(5):106344
pubmed: 33857539
Pharmacol Rev. 1995 Jun;47(2):331-85
pubmed: 7568331
CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):787-797
pubmed: 28657202
Cancer Res. 1990 Sep 1;50(17):5318-27
pubmed: 2386940
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7
pubmed: 26195508
Clin Pharmacokinet. 2019 May;58(5):545-564
pubmed: 30097887
J Antimicrob Chemother. 2017 Apr 1;72(4):1109-1117
pubmed: 28077672
Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11
pubmed: 23917322
Nat Commun. 2017 Dec 14;8(1):2129
pubmed: 29242552
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182535

Auteurs

Romain Aubry (R)

Université de Poitiers, PHAR2, Inserm U1070 , Poitiers, France.

Julien Buyck (J)

Université de Poitiers, PHAR2, Inserm U1070 , Poitiers, France.

Laure Prouvensier (L)

Université de Poitiers, PHAR2, Inserm U1070 , Poitiers, France.
Laboratoire de Toxicologie-Pharmacologie, CHU de Poitiers , Poitiers, France.

Jean-Winoc Decousser (J-W)

Department of Bacteriology and Infection Control, University Hospital Henri Mondor, Assistance Publique - Hôpitaux de Paris , Créteil, France.
Faculté de Médecine de Créteil, Ecole nationale vétérinaire d'Alfort (EnvA), EA 7380 Dynamyc Université Paris - Est Créteil (UPEC) , Créteil, France.

Patrice Nordmann (P)

Medical and Molecular Microbiology Unit, Faculty of Science and Medicine, University of Fribourg , Fribourg, Switzerland.
Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg , Fribourg, Switzerland.
Institute for Microbiology, University of Lausanne and University Hospital Centre , Lausanne, Switzerland.

Sebastian G Wicha (SG)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg , Hamburg, Germany.

Sandrine Marchand (S)

Université de Poitiers, PHAR2, Inserm U1070 , Poitiers, France.
Laboratoire de Toxicologie-Pharmacologie, CHU de Poitiers , Poitiers, France.

Nicolas Grégoire (N)

Université de Poitiers, PHAR2, Inserm U1070 , Poitiers, France.
Laboratoire de Toxicologie-Pharmacologie, CHU de Poitiers , Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH